Quality statement 1: Valproate
- Quality statement
- Quality measures
- What the quality statement means for service providers, healthcare professionals and commissioners
- What the quality statement means for service users and carers
- Source guidance
- Definitions of terms used in this quality statement
- Equality and diversity considerations
Women of childbearing potential are not prescribed valproate to treat a mental health problem.
Valproate is commonly used to treat epilepsy and some mental health problems. However, it can harm unborn babies when taken during pregnancy. Babies exposed to valproate in the womb are at a high risk of serious developmental disorders (approximately 30–40% of babies) and congenital malformations (approximately 10% of babies).
Valproate treatment must not be used in girls and women, including in young girls below the age of puberty, unless alternative treatments are not suitable and unless the conditions of the pregnancy prevention programme are met. Valproate must not be used in pregnant women. See also the Medicines and Healthcare products Regulatory Agency (MHRA) toolkit to ensure female patients are better informed about the risks of taking valproate during pregnancy.
Evidence of practice arrangements and written clinical protocols to ensure that women of childbearing potential are not prescribed valproate to treat a mental health problem.
Data source : Local data collection.
Proportion of women of childbearing potential prescribed valproate to treat a mental health problem.
Numerator – the number in the denominator prescribed valproate to treat a mental health problem.
Denominator – the number of women who are of childbearing potential.
Data source: Local data collection.
Service providers (primary care, community health services, general mental health services and specialist secondary care mental health services) have practice arrangements and written clinical protocols in place to ensure that women of childbearing potential are not prescribed valproate to treat a mental health problem.
Healthcare professionals (GPs and mental health professionals) do not prescribe valproate to women of childbearing potential to treat a mental health problem.
Commissioners of primary care and specialist and general mental health services (NHS England regional teams and clinical commissioning groups) specify within contracts that providers should not prescribe valproate to women of childbearing potential to treat a mental health problem.
Women who may become pregnant or who are pregnant should not be prescribed a medication called valproate to treat a mental health problem as it can harm unborn babies.
Antenatal and postnatal mental health (2014) NICE guideline CG192, recommendations 1.2.3 and 1.4.27
At the time of publication 3 formulations of valproate were available in the UK: sodium valproate and valproic acid (licensed for the treatment of epilepsy) and semi‑sodium valproate (licensed for the treatment of acute mania and continuation treatment in people whose mania responds to treatment). Both semi‑sodium and sodium valproate are metabolised to valproic acid (also known as valproate), which is the pharmacologically active component.
Childbearing potential should be determined for women on an individual basis. It should not be determined solely by age because childbearing potential can be dependent on factors other than age. It includes girls and young women under 18 and pregnant women.
[Adapted from Antenatal and postnatal mental health (NICE guideline CG192)]
When information is provided, there must be equal access to information for all women, including those with additional needs, such as physical or learning disabilities, and those who do not speak or read English. Women receiving information should have access to an interpreter or independent advocate if needed.